Politician trade (House)

Coherus Oncology (CHRS)Rep. Shri Thanedar (MI13) disclosed a sale $15K–$50K

Rep. Shri Thanedar (MI13) disclosed a sale of Coherus Oncology in the $15K–$50K range.

$15,001–$50,000
Reported range · official band, not an exact amount: 17 days
Disclosure lag

Traded: Jan 23, 2023
Disclosed: Feb 9, 2023

View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Coherus Oncology

OQRO holds no insider, Congress, fund or contract record for Coherus Oncology dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CHRS page.

Other recent filings by Rep. Shri Thanedar (MI13)

The full history of Rep. Shri Thanedar (MI13) is on the profile page.

How this filing works

The STOCK Act

Other disclosures at Coherus Oncology

SEC Form 4May 28, 2025

Everything OQRO holds on this company is on its CHRS page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO Pro Already have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data